Today's Trend
Seres Therapeutics, Inc. (NASDAQ: MCRB) shares appear to be getting support from a fresh analyst endorsement and upcoming clinical data, even as short-interest data remains a mixed signal.
- HC Wainwright initiated coverage on Seres Therapeutics with a Buy rating and a $12.00 price target, implying meaningful upside from the current share price. The firm also published earnings estimates that, while still negative, suggest continued analyst attention on the stock. HC Wainwright coverage and price target
- Seres announced it will host a webcast on July 8, 2026 to discuss top-line results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis, giving investors a near-term clinical catalyst to watch. Seres Therapeutics webcast announcement
- Short interest data showed a sharp decline to 219,815 shares as of June 15, down 54.1% from the prior reading, with only 2.4% of shares sold short. That suggests bearish positioning has eased, but it is not a direct operating update.
- Another short-interest update reported 0 shares sold short as of June 25, which appears inconsistent with the prior filing and likely reflects a data/reporting anomaly rather than a fundamental change.
- HC Wainwright’s estimates still point to substantial losses for Seres Therapeutics in 2026 through 2028, underscoring that the company remains far from profitability.
Overall, Seres Therapeutics (NASDAQ: MCRB) is being driven more by bullish analyst coverage and anticipation of clinical readouts than by current financial fundamentals, while the reduced short interest may also be helping sentiment.